Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00050505 · ClinicalTrials.gov registry record · Phase 2
Expanded Dryvax Dilution Study in Previously Vaccinated Adults
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 927
- Enrollment target
NCT00050505 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 927 participants.
The verdict
NCT00050505, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 927 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and effect of diluting smallpox vaccine, making a larger number of doses in case smallpox is released into the environment. A total of up to 927 healthy adults between the ages of 32 and 70 years who were already vaccinated against smallpox (but not since 1989) will volunteer for this study for up to 34 weeks and receive different strengths of vaccine. Some subjects may participate for longer if they choose to be revaccinated because the first vaccination does not take. The vaccine will be given by making small cuts in the skin and putting the vaccine into these cuts. After the screening visit, volunteers will be followed through study visits and follow up phone calls. Blood will be collected during some study visits to look at the immune system (body system that fights infection) response.
Interventions
- BIOLOGICAL Live vaccinia virus vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 927 participants |
| Start Date | 2002-10 |
| Est. Completion | 2003-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00050505
The ClinicalTrials.gov registry entry for NCT00050505 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 927 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Live vaccinia virus vaccine is the first listed.
NCT00050505 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00050505 about?
NCT00050505 is a clinical study titled "Expanded Dryvax Dilution Study in Previously Vaccinated Adults". The purpose of this study is to determine the safety and effect of diluting smallpox vaccine, making a larger number of doses in case smallpox is released into the environment. A total of up to 927 healthy adults between the ages of 32 and 70 years who were already vaccinated against smallpox (but n...
What is the current status of trial NCT00050505?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 927 participants. The study started on 2002-10. Estimated completion is 2003-12.
What interventions are being tested in trial NCT00050505?
The interventions under investigation include: Live vaccinia virus vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00050505?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.